Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Arjun Balar, M.D.
Hoosier Cancer Research Network
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Arizona at Dignity Health St. Joseph
Phoenix, Arizona, United States
- Rush University Medical Center
Chicago, Illinois, United States
- Healthpartners Institute
Minneapolis, Minnesota, United States
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
- New York University Clinical Cancer Center
New York, New York, United States
- Cleveland Clinic
Cleveland, Ohio, United States
- West Cancer Center University of Tennessee
Memphis, Tennessee, United States
- Froedtert & the Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 13 Sept 2017
- Primary completion
- 27 May 2021
- Completion
- 17 Mar 2022
- Last update posted
- 7 Jan 2025
- Registered enrollment
- 16
- Registry id
- NCT03272217
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.